References
- Hahn-Ast C, Glasmacher A, Mückter S, et al. Overall survival and fungal infection-related mortality in patients with invasive fungal infection and neutropenia after myelosuppressive chemotherapy in a tertiary care centre from 1995 to 2006. J Antimicrob Chemother 2010;65:761–768.
- Ram R, Wolach O, Vidal L, et al. Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric-inspired regimens: systematic review and meta-analysis. Am J Hematol 2012;87:472–478.
- De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813–1821.
- Marr KA, Leisenring W, Crippa F, et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood 2004;103:1557–1559.
- Harnicar S, Adel N, Jurcic J. Modification of vincristine dosing during concomitant azole therapy in adult acute lymphoblastic leukemia patients. J Oncol Pharm Pract 2009;15:175–182.
- Morris K, Weston H, Mollee P, et al. Outcome of treatment of adult acute lymphoblastic leukemia with hyperfractionated cyclophosphamide, doxorubicin, vincristine, dexamethasone/methotrexate, cytarabine:results from an Australian population. Leuk Lymphoma 2011;52:85–91.
- Hale KA, Shaw PJ, Dalla-Pozza L, et al. Epidemiology of paediatric invasive fungal infections and a case-control study of risk factors in acute leukaemia or post stem cell transplant. Br J Haematol 2010;149:263–272.
- Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies:the SEIFEM-2004 study. Haematologica 2006;91:1068–1075.
- Dignan FL, Evans SO, Ethell ME, et al. An early CT-diagnosis-based treatment strategy for invasive fungal infection in allogeneic transplant recipients using caspofungin first line: an effective strategy with low mortality. Bone Marrow Transplant 2009;44:51–56.
- Mikolajewska A, Schwartz S, Ruhnke M. Antifungal treatment strategies in patients with haematological diseases or cancer:from prophylaxis to empirical, pre-emptive and targeted therapy. Mycoses 2012;55:2–16.
- Illmer T, Babatz J, Pursche S, et al. Posaconazole prophylaxis during induction therapy of patients with acute lymphoblastic leukaemia. Mycoses 2011;54:e143–e147.
- Fielding AK. How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2010;116:3409–3417.
- Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348–359.
- Strevel EL, Ing DJ, Siu LL. Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol 2007;25:3362–3371.